In yesterday’s Wall Street session, Aligos Therapeutics Inc (NASDAQ:ALGS) shares traded at $0.58, down -3.33% from the previous session.
ALGS stock price is now -31.81% away from the 50-day moving average and -25.30% away from the 200-day moving average. The market capitalization of the company currently stands at $45.30M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target enhanced from $2 to $3, Piper Sandler Upgraded its rating from Neutral to Overweight for Aligos Therapeutics Inc (NASDAQ: ALGS). On January 06, 2023, Jefferies Upgraded its previous ‘Hold’ rating to ‘Buy’ on the stock increasing its target price from $2.50 to quote $3, while ‘Piper Sandler’ rates the stock as ‘Neutral’
In other news, Nuechterlein Carole, Director bought 7,933,601 shares of the company’s stock on Oct 25 ’23. The stock was bought for $6,004,149 at an average price of $0.76. Upon completion of the transaction, the Director now directly owns 11,025,941 shares in the company, valued at $6.4 million. A total of 32.22% of the company’s stock is owned by insiders.
During the past 12 months, Aligos Therapeutics Inc has had a low of $0.54 and a high of $1.22. As of last week, the company has a debt-to-equity ratio of 0.18, a current ratio of 6.25, and a quick ratio of 6.25. The fifty day moving average price for ALGS is $0.8449 and a two-hundred day moving average price translates $0.774475 for the stock.
The latest earnings results from Aligos Therapeutics Inc (NASDAQ: ALGS) was released for 2024-03-31. According to the Biotechnology Company, earnings per share came in at -0.43, beating analysts’ expectations of -0.49 by 0.06. This compares to -$0.54 EPS in the same period last year. The net profit margin was -722.06% and return on equity was -137.79% for ALGS. The company reported revenue of $0.99 million for the quarter, compared to $2.72 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -63.79 percent.
